Hollandbio welcomes NovoSere

Hollandbio connects, represents and supports the Dutch biotech sector. We are very proud to represent more than 270 companies: from start-ups, small and medium-sized enterprises, to large companies, active in health, nutrition or biobased economy. Today we welcome our newest member, NovoSere. NovoSere is a consultancy firm, specialized in pharmaceutical Chemistry, Manufacturing and Control (CMC). NovoSere was founded by a team of four experts with complementary scientific backgrounds and a great synergy in their way of working. A few words from NovoSere itself:

About our name
A ‘sere’ is the sequence of species that transform bare ground into a thriving ecosystem. Each sere stage brings new life forms, paving the way for the next, until reaching a stable climax. We form a seral community with our clients, transforming their concepts to medicinal products, thus helping them progress from one stage to the next.

Why we join hollandbio

Both hollandbio and NovoSere share the ambition to enable the growth and maturation of biotechnological innovation. We are part of the same ecosystem. The vision of hollandbio to contribute to the success of the Biotech sector through connection, support, and by providing clear routes from lab to market resonates perfectly with ours.

What we deliver

CMC in pharmaceuticals is a multifaceted discipline that integrates the science of chemistry with the complexities of manufacturing and stringent regulatory controls. It includes various aspects such as defining the formulation, setting up the manufacturing process, implementing analytics, and incorporating robust quality control measures. In simpler words, it is a term to describe everything related to making sufficient medicinal products of the right, proven quality to provide people with a product that is safe and effective.

NovoSeres scalable, integrated team of CMC experts provides strategic and operational support, expert guidance for selection and management of contract development and manufacturing organizations, and solutions to address our clients’ needs related to both capacity and capability issues. We are committed to streamlining development from discovery to market, helping our partners accelerate clinical milestones and maximize the value of their assets.